Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) (STRIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02378753
Recruitment Status : Completed
First Posted : March 4, 2015
Results First Posted : April 5, 2018
Last Update Posted : April 5, 2018
Sponsor:
Collaborators:
University of Sierra Leone
Ministry of Health and Sanitation, Sierra Leone
Department of Health and Human Services
eHealth Africa
Information provided by (Responsible Party):
Centers for Disease Control and Prevention

Brief Summary:

The 2014 outbreak of Ebola in West Africa is the largest in recorded history with widespread and intense transmission in Guinea, Liberia, and Sierra Leone. The high infectivity of blood and secretions, lack of appropriate personal protective equipment (PPE) and challenges in following infection control and prevention protocols put healthcare workers at high risk during outbreaks, and direct contact with the bodies of deceased Ebola victims can also sustain community transmission. This study will accelerate introduction and use of monovalent recombinant vesicular stomatitis virus Ebola vaccine (rVSVΔG-ZEBOV) among healthcare workers and frontline personnel involved in the Ebola outbreak response in Sierra Leone, while concurrently evaluating the safety and efficacy of the vaccine.

This is an unblinded, randomized trial with phased vaccine introduction in the target population. Participation in the study will be voluntary and open to adults 18 years of age and older who are at high risk of exposure to Ebola infection through their daily work and who work in a selected study area.


Condition or disease Intervention/treatment Phase
Hemorrhagic Fever, Ebola Biological: rVSVΔG-ZEBOV Phase 2 Phase 3

Detailed Description:

The Ebola outbreak was confirmed in March 2014 with widespread and intense transmission in Guinea, Liberia, and Sierra Leone. While there are no U.S. Food and Drug Administration (FDA)-approved pharmaceuticals to prevent or treat Ebola, two candidate vaccines are being tested in humans for dosing, tolerability, and safety. This study will evaluate monovalent recombinant vesicular stomatitis virus Ebola vaccine that remains replication competent (rVSVΔG-ZEBOV) in Sierra Leone.

The high infectivity of blood and secretions, lack of appropriate personal protective equipment (PPE) and challenges in following infection control and prevention protocols put healthcare workers at high risk during outbreaks, and direct contact with the bodies of deceased Ebola victims can also sustain community transmission.

This unblinded, randomized trial will evaluate vaccine efficacy (VE) and safety with phased vaccine introduction in the target population. Participation in the study will be voluntary and open to adults 18 years of age and older who are at high risk of exposure to Ebola infection through their daily work and who work in a selected study area. This includes: 1) personnel working in healthcare facilities where care is provided for Ebola patients; 2) personnel working in non-Ebola healthcare facilities who may have exposure to undiagnosed Ebola-infected individuals; and 3) personnel working in one of the following job categories: surveillance team, ambulance team, or laboratory worker responsible for swabbing deceased persons. Staff members involved in this study are also eligible to receive the vaccine under this protocol; study staff will be followed for 6 months post-vaccination to monitor for safety of rVSVΔG-ZEBOV.

Eligible participants within a healthcare facility or frontline team will be enrolled and individually randomized to either immediate or deferred vaccination. A single dose of rVSVΔG-ZEBOV will be administered intramuscularly. Immediate vaccination is defined as vaccination within 7 days of enrollment and deferred vaccination is defined as vaccination at the end of an 18-24 week follow-up period. Participants will not be blinded to the randomized assignment of immediate or deferred vaccination. All enrolled participants will have the opportunity to receive rVSVΔG-ZEBOV by the end of the study. Enrollment and vaccination will be phased over time.

Ebola events that occur during the 18-24 week post-enrollment will be included in the VE analysis, with the immediate vaccination arm contributing vaccinated follow-up time and the deferred vaccination arm contributing unvaccinated follow-up time. All participants, regardless of randomized assignment, will be followed for 6 months after vaccination to monitor for safety of rVSVΔG-ZEBOV.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8651 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: [rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone
Study Start Date : April 2015
Actual Primary Completion Date : November 8, 2016
Actual Study Completion Date : December 5, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ebola

Arm Intervention/treatment
Experimental: rVSVΔG-ZEBOV (immediate vaccination)
One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units)
Biological: rVSVΔG-ZEBOV
The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
Other Name: BPSC-1001

Experimental: rVSVΔG-ZEBOV (deferred vaccination)
One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
Biological: rVSVΔG-ZEBOV
The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
Other Name: BPSC-1001




Primary Outcome Measures :
  1. Laboratory-confirmed Ebola (Study Diagnostics) [ Time Frame: > 21 days following vaccination ]

    Incidence of Ebola confirmed by the STRIVE study laboratory in each treatment group during the Randomized Portion of the trial. For the vaccine efficacy endpoint, all enrolled participants in both arms were followed for 18-24 weeks after enrollment (after which point participants in the deferred cohort received crossover vaccination). Statistical analysis was to proceed as survival analysis (time-to-event/time-to-infection) of cohort follow-up data during this period.

    There were no laboratory-confirmed cases of Ebola among study participants, so therefore no efficacy analyses were performed.


  2. Number of Participants With Occurrence of Serious Adverse Events During the 6 Months Following the Vaccination [ Time Frame: 6 months following vaccination ]
    Number of Participants with Occurrence of SAEs within the 6-month follow-up period following a single dose of rVSVΔG-ZEBOV. Vaccination in the immediate group occurred within 7 days of enrollment if possible, and vaccination in the deferred-vaccination group occurred 18-24 weeks after enrollment.


Secondary Outcome Measures :
  1. Death Due to Laboratory-confirmed Ebola [ Time Frame: 6 months following vaccination ]
    Deaths due to Ebola confirmed by the STRIVE study laboratory in each treatment group during the Randomized Portion of the trial. There were no laboratory-confirmed cases of Ebola among study participants, so therefore no efficacy analyses were performed.

  2. Ebola Confirmed by Non-study or Study Diagnostics [ Time Frame: 6 months following vaccination ]
    Incidence of Ebola confirmed by the STRIVE study laboratory or by a non-study laboratory in each treatment group during the Randomized Portion of the trial. For the vaccine efficacy endpoint, all enrolled participants in both arms were followed for 18-24 weeks after enrollment (after which point participants in the deferred cohort received crossover vaccination). Statistical analysis was to proceed as survival analysis (time-to-event/time-to-infection) of cohort follow-up data during this period. There were no laboratory-confirmed cases of Ebola among study participants, so therefore no efficacy analyses were performed.

  3. Suspected, Probable or Laboratory-confirmed Ebola [ Time Frame: 6 months following vaccination ]
    Incidence of suspected, probable, or laboratory-confirmed Ebola, where "suspected" and "probable" cases are defined by the August 9, 2014 World Health Organization case definition recommendations for use during an Ebola outbreak, and laboratory-confirmed Ebola includes both study laboratory and non-study laboratory diagnostics. An Ebola Screening Form was required to be completed for all participants referred for evaluation of suspected Ebola; the Outcome Measure (Count of Participants) reflects the number of participants in each group for whom an Ebola Screening Form was completed.

  4. Number of Participants With Occurrence of Solicited Injection-site and Systemic Reactogenicity Signs and Symptoms, Including Fever, on Vaccination Day and During the 7 Days Following the Vaccination or Enrollment. [ Time Frame: Vaccination day and for 7 days following vaccination ]
    Solicited symptoms were assessed only in safety sub-study participants (the first 449 participants enrolled at the COMAHS Library site), during the 7 days after vaccination (immediate group) or after enrollment without vaccination (deferred group). Participants were actively solicited for the occurrence of local (injection-site) pain, redness, and swelling and the following systemic reactogenicity symptoms: fever, joint pain, joint swelling, muscle pain, fatigue, feeling unwell, chills, headache, vomiting, nausea, diarrhea, abdominal pain, rash, oral ulcers, and skin vesicles (blisters).

  5. Number of Participants With Occurrence of Solicited and Unsolicited AEs During the 28 Days Following the Vaccination or Enrollment [ Time Frame: During 28 days following vaccination ]
    Solicited local and systemic reactogenicity symptoms and unsolicited adverse events were assessed in safety sub-study participants (the first 449 participants enrolled at the COMAHS Library site), during the 28 days after vaccination (immediate group) or after enrollment without vaccination (deferred group).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 18 years or older.
  2. Member of target population at the time of enrollment:

    • active worker in an Ebola care, holding, or treatment center (may include physicians, nurses, nurse aides, lab technicians, pharmacists, pharmacy technicians, cleaners, and security and administrative staff);
    • active worker in a facility providing non-Ebola-related healthcare (may include physicians, nurses, nurse aides, lab technicians, pharmacists, pharmacy technicians, cleaners, and security and administrative staff);
    • active frontline worker in one of the following job categories: surveillance team, ambulance team, burial worker, or worker responsible for swabbing deceased persons.
  3. Reasonably anticipates living in Sierra Leone for the 18-24 weeks following enrollment.
  4. Reachable by phone throughout the 6 month post-vaccination safety follow-up period.
  5. Willing to adhere to personal protective equipment (PPE) and infection control recommendations.
  6. Able and willing to complete the informed consent process and study procedures.
  7. Willing to receive vaccine in either the immediate or the deferred trial arms, according to random assignment.

Exclusion Criteria:

  1. History of Ebola (self-report).
  2. Prior receipt of experimental Ebola or Marburg vaccine.
  3. History of human immunodeficiency virus (HIV) or clinically important immunodeficiency (self-report).
  4. Any history of allergy or anaphylaxis to prior vaccines
  5. Breast-feeding an infant or child.
  6. Any reason the investigator suspects that data collected from this person would be incomplete or of poor quality.
  7. Current pregnancy (a negative urine pregnancy test is required for women participants <50 years of age who self-report as not pregnant).
  8. Currently being followed for known exposure to Ebola.
  9. Known experimental research agents or other vaccine within 28 days (4 weeks) before vaccination.
  10. Fever ≥ 38.0°C (100.4°F) at time of vaccination.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02378753


Locations
Layout table for location information
Sierra Leone
College of Medicine and Allied Health Sciences (COMAHS)
Freetown, Western Area Urban, Sierra Leone
Bombali
Bombali District, Sierra Leone
Port Loko
Port Loko District, Sierra Leone
Tonkolili
Tonkolili District, Sierra Leone
Western Area Rural
Western Area District, Sierra Leone
Sponsors and Collaborators
Centers for Disease Control and Prevention
University of Sierra Leone
Ministry of Health and Sanitation, Sierra Leone
Department of Health and Human Services
eHealth Africa
Investigators
Layout table for investigator information
Principal Investigator: Mohamed Samai, MBChB,PhD University of Sierra Leone

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT02378753    
Other Study ID Numbers: CDC-NCIRD-6689
First Posted: March 4, 2015    Key Record Dates
Results First Posted: April 5, 2018
Last Update Posted: April 5, 2018
Last Verified: July 2016

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Keywords provided by Centers for Disease Control and Prevention:
Ebola
Sierra Leone
vaccine
rVSVΔG-ZEBOV
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhagic Fever, Ebola
Hemorrhagic Fevers, Viral
RNA Virus Infections
Virus Diseases
Filoviridae Infections
Mononegavirales Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs